US FDA's Califf On Real-World Evidence: 'Use It For The Right Purposes'
This article was originally published in SRA
Executive Summary
Randomized clinical trials have long been extolled as the gold standard for establishing drug efficacy and safety. However, US Food and Drug Administration Commissioner Robert Califf has his sights set on increased use of another type of research for informing regulatory decision-making: randomized clinical practice studies.
You may also be interested in...
Califf Outlines Clinical Trial Reform Message, Which Could Travel With Him To Commissioner’s Office
US FDA commissioner-nominee Califf calls for streamlining clinical trial bureaucracy, as well as open access to clinical data.
Califf Likely To Find Many Familiar Problems Upon Return To US FDA Helm
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.
Robert Califf Likely To Find Many Familiar Problems Upon His Return To US FDA
President Biden’s pick for FDA commissioner should remember many of the hot-button issues that he would face upon confirmation, such as drug pricing and approval standards.